PCI Biotech has announced that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with cytokines.
Cytokines are small proteins that are involved in cell signaling, and that are very important in the immune system, modulating both cell-based and humoral immune responses. The combination of cytokines with PCI Biotech’s vaccine technology, fimaVacc, has been shown to be effective for enhancing cellular immune responses that are important for the effect of therapeutic vaccines. The now granted US patent gives broad coverage for the combination of various cytokines with the fimaVacc technology.
Protection until 2035
“There are many vaccines under development utilizing cytokines to elicit immune responses. The US patent granted is important for PCI Biotech’s development strategy, as it supplements our ability to generate an internal future vaccine pipeline, in addition to bringing value for the fimaVacc technology in partnering efforts,” says Per Walday, CEO of PCI Biotech.
As part of PCI Biotech’s strategy for applying the PCI-technology for therapeutic cancer vaccines, several global patent applications were filed in 2013 and 2014. The granted US patent secure protection until 2035 and this patent application is still pending in Europe and key Asian markets.
Photo of Per Walday: PCI Biotech